Insight of immune checkpoint blockades in melanoma: mechanism and clinical translation
Qingyan Zhang, Chunhui Yuan, Lin Zhu, Shaobing Zheng, Yantao Xu, Xuanlin Che, Shiyu Xiao, Juan Liu, Hong Liu, Hui Li, Xiang Chen · 2026
Read Insight of immune checkpoint blockades in melanoma: mechanism and clinical translation by Qingyan Zhang, Chunhui Yuan, Lin Zhu, Shaobing Zheng, Yantao Xu, Xuanlin Che, Shiyu Xiao, Juan Liu, Hong Liu, Hui Li, Xiang Chen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13471329.txt.
Description
Zhang and co-authors review how immune checkpoint blockade, a drug approach that releases the brakes on immune cells, has reshaped treatment for melanoma, the deadliest skin cancer. Their 2026 survey covers the main checkpoint drugs, how they work, and what major trials found, while weighing side effects and drug resistance.
Melanoma makes up only about 4% of skin cancers yet causes roughly 75% of skin cancer deaths, the authors note. In one key trial, pembrolizumab produced responses in 33% of patients versus 12% for ipilimumab, and patients lived a median of 32.7 months rather than 15.9 months on the older drug. Ten-year data for combined nivolumab plus ipilimumab show a median survival of 71.9 months, far above 19.9 months for ipilimumab alone, though the stronger mix brings heavier immune side effects. Personalized choices, they argue, are now the central challenge.
Catalog record
| CREATOR | Qingyan Zhang, Chunhui Yuan, Lin Zhu, Shaobing Zheng, Yantao Xu, Xuanlin Che, Shiyu Xiao, Juan Liu, Hong Liu, Hui Li, Xiang Chen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 133 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |